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Abstract
Background: Administration of the N-methyl-D-aspartate (NMDA) antagonist ketamine during the
perinatal period can produce a variety of behavioral and neuroanatomical changes. Our laboratory has
reported reliable changes in learning and memory following a single dose of ketamine administered late in
gestation. However, the nature of the drug-induced changes depends on the point during embryonic
development when ketamine is administered. Embryonic day 18 (E18) rat fetuses pre-treated with
ketamine (100 mg/kg, i.p. through the maternal circulation) and taught a conditioned taste aversion (CTA)
learn and remember the CTA, whereas E19 fetuses do not. The current study sought to determine if long-
term behavioral effects could be detected in animals that received ketamine or a saline control injection
on either E18 or E19. Rat behavior was evaluated on two different measures: spontaneous locomotion and
water maze learning. Measurements were collected during 2 periods: Juvenile test period [pre-pubertal
locomotor test: Postnatal Day 11 (P11); pre-pubertal water maze test: P18] or Young-adult test period
[post-pubertal locomotor test: P60; post-pubertal water maze test: P81].
Results: Water maze performance of ketamine-treated rats was similar to that of controls when tested
on P18. Likewise, the age of the animal at the time of ketamine/saline treatment did not influence learning
of the maze. However, the young-adult water maze test (P81) revealed reliable benefits of prenatal
ketamine exposure – especially during the initial re-training trial. On the first trial of the young adult test,
rats treated with ketamine on E18 reached the hidden platform faster than any other group – including
rats treated with ketamine on E19. Swim speeds of experimental and control rats were not significantly
different. Spontaneous horizontal locomotion measured during juvenile testing indicated that ketamine-
treated rats were less active than controls. However, later in development, rats treated with ketamine on
E18 were more active than rats that received the drug on E19.
Conclusion: These data suggest that both the day in fetal development when ketamine is administered
and the timing of post-natal behavioral testing interact to influence behavioral outcomes. The data also
indicate that the paradoxical age-dependent effects of early ketamine treatment on learning, previously
described in fetuses and neonates, may also be detected later in young adult rats.
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Background
Administration of ketamine or other NMDA receptor
blocking drugs [1] may bring with it both beneficial and
problematic outcomes. Ketamine's use as a dissociative
anesthetic is well established in clinical practice [1] and
more recently, it has also been proposed as a neuropro-
tectant against hypoxic-ischemic brain damage in neona-
tal rats [2]. However, in adult animals, NMDA receptor
blockade is known to produce psychotomimetic side
effects [3], impair memory formation [4-7], and may pro-
duce neurotoxicity [3,8-11]. This neurotoxicity is evi-
denced by vacuolization of cortical neurons [3,10] and
has also been linked to programmed cell death (apopto-
sis) during development [12-14].
The toxic effects of NMDA receptor blockade are appar-
ently dependent on the dose of the drug, administration
regimen, and the age of the animal treated. For example,
vulnerability to MK-801-induced cortical vacuolization is
not evident in fetal animals but rather begins at approxi-
mately the time of puberty [8]. On the other hand, apop-
togenic effects of ketamine have been seen following drug
administrations during the last trimester of pregnancy
[12]. Further, the selection of an acute or chronic dosing
regimen may also modulate the neurobehavioral out-
comes and the permanence of the neurological changes
that can be expected [9,13,15-18].
Recent experiments from our laboratory have focused on
age-dependent effects of a single dose of ketamine on fetal
learning and memory. Rat fetuses can learn conditioned
taste aversions (CTAs) and exhibit taste-mediated condi-
tioned motor responses (CMRs) [19,20], which can be
modulated in complex ways by exposure to ketamine at
different times during the perinatal period [20,21]. For
example, ketamine will either cause a potentiation or a
blockade of memory formation in rats, depending on the
specific day during fetal development when the drug is
administered. Rat fetuses that receive ketamine on E18
(30-minutes before CS-US pairing) are able to learn and
remember CTAs and CMRs quite well. However, rat
fetuses that receive ketamine before CTA training just one
day later, on E19, exhibit an amnesia for these condi-
tioned responses [21,22]. We have referred to this phe-
nomenon as the "ketamine paradox" [21].
These previous studies have only tested the durability of
the ketamine paradox over a period of up to 2 weeks [22]
and have looked at a very narrow range of behavioral
measures – all with gustatory components. However,
there are some indications that early treatment with
NMDA receptor blocking drugs can have long-term
behavioral implications. For example, neonatal treatment
with MK-801 can produce long-lasting behavioral radio-
protection in rats with x-ray-induced hippocampal dam-
age [23]. Likewise, Maier et al. [24] have reported that
MK801-induced NMDA receptor antagonism in young
rats (P7-17) extends the sparing of hindlimb function
after spinal transection in older animals. However, treat-
ment with an NMDA receptor antagonist [(+)HA-966] for
a longer time, later in neonatal development (P10-20),
impaired motor and cognitive behaviors in adult rats [25].
Several questions remain. What is the range of behaviors
that can be influenced by ketamine treatment during the
perinatal period? How long lasting are the different
behavioral effects of ketamine administered late in
gestation?
The current study extends our original observations and
reports how a single injection of ketamine on either E18
or E19 modulates spontaneous locomotor activity and
performance in a water maze. We tested the rats as juve-
niles and then as young adults. Our data suggest several
age-dependent effects of early ketamine treatment –
effects that depend on not only the length of time between
drug administration and behavioral testing but also on
the day in embryonic development when the NMDA
receptor antagonist was administered.
Results
Water maze
P18 water maze test
Over the10 trials of the water maze test, subjects signifi-
cantly reduced their latencies to mount the hidden plat-
form [F(9, 102) = 4.233; p < 0.0001] indicating the
gradual learning of the maze. However, as Figure 1A illus-
trates, the animals never gained real proficiency on this
task. The latencies decreased most dramatically within the
first 3 trials and therefore we undertook a more in-depth
analysis of this portion of the study. We also noticed that,
as the animals swam, they would sometimes stop and
tread water against the side of the tank. Therefore, we
undertook an analysis of the stop time/trial during the
first 3 water maze trials (see Figure 2). The time spent
treading water decreased significantly over the first 3 trials
[F(2, 111) = 18.359; p < 0.001]. There was also a signifi-
cant drug effect indicating that ketamine-treated rats spent
less time treading water than did saline-treated controls
[F(1, 153) = 15.972; p < 0.001]. This effect was independ-
ent of the age at which the rats received ketamine.
Time spent treading water at the side of the tank may be
interpreted as an alternative, futile, escape strategy and
not necessarily as an indicator of learning the position of
the hidden platform. Subsequent analyses subtracted out
stop-times in order to provide the most accurate portrayal
of maze learning during the first 3 trials. With stop-time
removed, the declining time-to-platform [F(2, 102) =
3.501; p = 0.034] and swimming distance [F(2, 102) =
4.632; p = 0.012] over the first 3 trials indicated a learningBMC Pharmacology 2004, 4:28 http://www.biomedcentral.com/1471-2210/4/28
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Time to mount a hidden platform during the first (juvenile; panel A) and second (young-adult; panel B) water maze test Figure 1
Time to mount a hidden platform during the first (juvenile; panel A) and second (young-adult; panel B) water 
maze test. Rats were treated (through the maternal circulation) with either 100 mg/kg ketamine HCl (i.p.) or saline on either 
E18 or E19 and then tested later on P18 and P81. The data presented here illustrate raw latencies without taking into account 
the time the animals spent treading water (i.e., not making forward progress). Panel A: P18 rats generally decreased their 
latencies to mount the hidden platform over the 10 trials. This effect was most prominent over the first 3 trials. The behavioral 
changes induced by drug or age manipulations were not statistically significant. Panel B: P81 rats all readily re-learned the 
location of the hidden platform as there was a significant reduction in time to mount the platform over the 10 trials. The anal-
ysis (see text) also revealed a significant Age X Drug interaction which was most prominent on trial 1 (see also Figure 3). Data 
were analyzed using a three-way ANOVA [Drug (100 mg/kg ketamine HCl, saline control) X Treatment age (E18, E19) X 
Time] with time blocks as the repeated time factor and compensation for unequal Ns. Variance indicators are the Standard 
Error of the Mean (SEM).
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of the maze during this initial exposure to the apparatus.
However the behavioral changes induced by drug or age
manipulations were not statistically significant. The
number of trials in which the rat failed to mount the plat-
form within 90 seconds was not significantly different
among the 4 treatment groups. Likewise, swim speed did
not decrease significantly over the first 3 maze trials indi-
cating that the animals were not fatiguing as they under-
took multiple swims.
Once the rat mounted the hidden platform we timed how
long the subject remained there before it was removed
(maximum of 30 seconds). An analysis of these data dur-
ing the first 3 maze trials revealed neither a significant
influence of subject age nor drug treatment.
P81 water maze test
An analysis of the second water maze test indicated that
there was a significant reduction in time [F(9, 157) =
26.868; p < 0.001] to mount the hidden platform over the
10 trials (see Figure 1B). The analysis also revealed a sig-
nificant Age X Drug interaction [F(1, 401) = 5.15; p =
0.024] but no significant main effects of drug or age at
treatment. Rats had previous experience with the maze
(see P18 maze data) and inspection of the data indicated
that, after the first trial, latencies in all groups converged
Time spent treading water (i.e., not making forward progress) during the P18 water maze test Figure 2
Time spent treading water (i.e., not making forward progress) during the P18 water maze test. There was a gen-
eral decline in the time spent treading water as the animals learned the maze. Ketamine-treated rats spent the least time exhib-
iting this behavior. Rats treated with the NMDA-receptor blocking drug on E18 stopped swimming for the shortest period and 
made more-constant progress towards the hidden platform. Data were analyzed using a three-way ANOVA [Drug (100 mg/kg 
ketamine HCl, saline control) X Treatment age (E18, E19) X Time] with time blocks as the repeated time factor and compen-
sation for unequal Ns. Variance indicators are the Standard Error of the Mean (SEM).
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Time to mount the hidden platform (top panel) and swimming distance to the platform (bottom panel) during the first trial of  the second (young-adult) water maze test Figure 3
Time to mount the hidden platform (top panel) and swimming distance to the platform (bottom panel) during 
the first trial of the second (young-adult) water maze test. Rats were treated (through the maternal circulation) with 
either 100 mg/kg ketamine HCl (i.p.) or saline on either E18 or E19 and then tested later on P81. The temporal data presented 
here do not include time spent treading water but rather represent only the time that the rats were making forward progress. 
Ketamine-treated rats found the platform significantly faster than saline controls and swam shorter distances to do so. Group 
comparisons indicated that rats treated with ketamine on E18 or E19 reached the hidden platform significantly faster and swam 
shorter distances than saline-treated controls (* = p ≤ 0.05; NS = non-significant group differences). Further, E18 rats treated 
with ketamine later exhibited a shorter latency to reach the hidden platform than did E19 rats treated with ketamine. Data 
were analyzed using a two-way ANOVA [Drug (100 mg/kg ketamine HCl, saline control) X Treatment age (E18, E19)]. Individ-
ual group comparisons were accomplished by using t-tests employing the Bonferroni compensation for multiple comparisons. 
Variance indicators are the Standard Error of the Mean (SEM).BMC Pharmacology 2004, 4:28 http://www.biomedcentral.com/1471-2210/4/28
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and dropped dramatically. As in the P18 water maze anal-
ysis, stop times (i.e., time spent treading water) during
this first trial were significantly lower in ketamine-treated
rats [Drug effect: F(1, 62) = 6.645; p = 0.012]. A subse-
quent examination of the data excluded the time spent
treading water in swim-time, swim-distance and swim-
speed analyses. On the first trial (see Figure 3), ketamine-
treated rats found the platform significantly faster than
saline controls [Drug effect: F(1, 67) = 7.28; p = 0.009]
and swam shorter distances to do so [Drug effect: F(1, 67)
= 8.89; p = 0.004]. Animals injected on E18 were generally
quicker to find the platform [Treatment Age effect: F(1,
67) = 10.55; p = 0.002] and swam more direct routes to
the platform [Treatment Age effect: F(1, 67) = 5.89; p =
0.018] than were animals injected on E19.
Post-hoc analyses indicated that rats treated with keta-
mine on E18 reached the hidden platform significantly
faster and swam shorter distances than saline-treated con-
trols as well as rats treated with ketamine on E19 (see Fig-
ure 3). Rats treated with ketamine (on either E18 or E19)
also exhibited significantly fewer failures to reach the hid-
den platform (within the 90-second limit/trial) than did
saline control animals [t(66) = 1.86, p = 0.034 (one-tail
test)]: ketamine-treated Mean ± SEM = 0.71 ± 0.05 fail-
ures/10 trials; saline-treated Mean ± SEM = 0.24 ± 0.07
failures/10 trials.
The short latencies to mount the platform cannot be
attributed to faster swimming speeds. On the first, second
and third water maze trials (i.e., the only ones analyzed
for swim speeds), P81 rats that were treated with ketamine
on E18 did not swim significantly faster than any of the
animals in the other treatment groups. For example, the
swim speeds for trial 1 were: [E18/ketamine: 34.30 ± 3.59
cm/sec; E18/saline: 37.97 ± 1.85 cm/sec; E19/ketamine:
30.47 ± 2.40 cm/sec; E19/saline: 32.92 ± 2.23 cm/sec
(Mean ± SEM)]. Fatigue did not seem to play a role in the
group differences since swim speed remained stable in all
groups over the first 3 water maze trials on P81.
Locomotion
A single ketamine treatment during the perinatal period
had long-lasting effects on spontaneous locomotor move-
ments. Ketamine's effects depended on the age of behav-
ioral testing as well as the age of the drug treatment.
Horizontal movements (i.e., line crossings) were more
prominently influenced by perinatal ketamine than were
vertical movements (rearing).
P11 locomotor tests
P11 rats treated prenatally with ketamine showed habitu-
ation to the open-field test chamber and exhibited
reduced horizontal movements overall (see Figure 4).
After being placed in the activity chamber, P11 rats
decreased their horizontal movements (i.e., line crossings
analyzed in 6, 5-minute blocks) significantly over the 30-
minute test session [F(5, 405) = 80.66, p < 0.0001]. In
fact, locomotor activity of all treatment groups was
reduced to very low levels (typically <5 line breaks/min)
after the first 5 minutes (Figure 4B).
Ketamine-treated rats were also generally less active than
saline-injected controls [F(1, 81) = 7.79, p = 0.007]. How-
ever, there was a significant interaction between drug
treatment and the block of time in which the locomotor
measurement was made [F(5, 405) = 6.26, p = 0.0002]. At
the end of 5 minutes, P11 rats reduced their spontaneous
locomotion to approximately 20% of its original level. For
this reason, we performed a minute-by-minute analysis of
the first 5 minutes in the open field apparatus (see Figure
4B). Once again, there was a significant decrease in hori-
zontal movement over the first 5 minutes in the chamber
[F(4, 336) = 143.13, p < 0.001]. Generally, ketamine treat-
ment caused a significant decrease in line crossings as
compared to saline-injected controls [Drug effect = F(1,
84) = 12.77, p = 0.0006]. A Drug X Time Block interaction
[F(4, 336 = 3.21, p = 0.01] revealed that the largest group
differences were exhibited within the first 3 minutes (see
Figure 4B for individual group comparisons). There was
not a significant difference in the spontaneous horizontal
locomotor responses of E18- and E19-ketamine treated
rats.
P60 locomotor tests
Horizontal movements of ketamine-treated rats tested on
P60 varied depending on when, during the fetal period,
they had received the drug (see Figure 5). As was the case
during the P11 tests, horizontal movements decreased sig-
nificantly over the 30-minute test [F(5, 340) = 163.12, p <
0.0001]. There was both an overall effect of subject age at
time of drug injection [F(1, 68) = 4.37, p = 0.04] and a
Treatment Age X Drug interaction [F(1, 68) = 10.37, p =
0.002]. Over the course of this 30-minute test (Figure 5A),
E18 fetuses treated with ketamine were generally more
active in their horizontal movements than were animals
treated with saline on this day of embryonic develop-
ment. Further, rats exposed to ketamine on E18 exhibited
significantly more horizontal movement than did E19 rats
treated with either saline or ketamine. Rats injected with
saline on E18 or E19 did not exhibit significant differ-
ences in line crossings when tested on P60.
An analysis that focused on the first 5-minutes of this P60
locomotor test (Figure 5B) revealed a significant interac-
tion between drug treatment and subject age at time of
treatment [F(1, 70) = 14.13, p < 0.001]. Multiple compar-
isons revealed that rats treated with ketamine on E18 were
more active than both E18 saline-control rats and E19 rats
that received ketamine. These data reveal a very differentBMC Pharmacology 2004, 4:28 http://www.biomedcentral.com/1471-2210/4/28
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Spontaneous horizontal locomotor activity of P11 rats treated (through the maternal circulation) with either 100 mg/kg keta- mine HCl (i.p.) or saline on either E18 or E19 Figure 4
Spontaneous horizontal locomotor activity of P11 rats treated (through the maternal circulation) with either 
100 mg/kg ketamine HCl (i.p.) or saline on either E18 or E19. Panel A illustrates the entire 30-minute test. In only 
the initial 5-minute observation period, rats treated with ketamine in utero crossed significantly fewer lines than did the saline 
control animals. After this initial period of habituation, indicators of horizontal movement declined and group scores con-
verged. Panel B is a minute-by-minute illustration of the first 5 minutes of locomotor activity. In a time-dependent manner, 
rats treated with ketamine in utero crossed significantly fewer lines than did the control animals. Habituation to the open field is 
represented by a rapid decline in movement. * = Significantly different from E18/saline group; + = significantly different from 
E19/saline group. Data were analyzed using a three-way ANOVA [Drug (100 mg/kg ketamine HCl, saline control) X Treatment 
age (E18, E19) X Time] with time blocks as the repeated time factor and compensation for unequal Ns. If the repeated-meas-
ure ANOVA revealed a significant trial effect (indicating a change over time) a two-way ANOVA [Drug (100 mg/kg ketamine 
HCl, saline control) X Treatment age (E18, E19)] was run to analyze the group differences during a particular trial. Individual 
group comparisons were accomplished by using the Tukey-Kramer test for Multiple Comparisons. An α = 0.05 was used 
throughout these analyses. Variance indicators are the Standard Error of the Mean (SEM).
A
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Horizontal locomotion of P60 rats treated (through the maternal circulation) with either 100 mg/kg ketamine HCl (i.p.) or  saline on either E18 or E19 Figure 5
Horizontal locomotion of P60 rats treated (through the maternal circulation) with either 100 mg/kg ketamine 
HCl (i.p.) or saline on either E18 or E19. Panel A illustrates the entire 30-minute test. E18 rats treated with ketamine 
were significantly more active than were animals in the other treatment groups. These effects were most prominent at partic-
ular time periods. * = Significantly different from E18/saline group; # = significantly different from E19/ketamine group. + = sig-
nificantly different from E19/saline group. Panel B is a minute-by-minute illustration of the first 5 minutes of locomotor 
activity. In all treatment groups, there is a significant decline in locomotion over the first 5 minutes of testing. There is also a 
significant interaction between drug treatment and subject age at time of treatment – indicating that rats treated with ketamine 
on E18 are more active than both E18 saline-control rats and E19 rats that received ketamine. Data were analyzed using a 
three-way ANOVA [Drug (100 mg/kg ketamine HCl, saline control) X Treatment age (E18, E19) X Time] with time blocks as 
the repeated time factor and compensation for unequal Ns. If the repeated-measure ANOVA revealed a significant trial effect 
(indicating a change over time) a two-way ANOVA [Drug (100 mg/kg ketamine HCl, saline control) X Treatment age (E18, 
E19)] was run to analyze the group differences during a particular trial. Individual group comparisons were accomplished by 
using the Tukey-Kramer test for Multiple Comparisons. An α = 0.05 was used throughout these analyses. Variance indicators 
are the Standard Error of the Mean (SEM).
A
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pattern of horizontal locomotor responses exhibited by
ketamine-treated rats depending on the day during fetal
development that they received the drug. There were no
significant group differences in rearing movements on
P60.
Discussion
The data presented here suggest several age-dependent
effects of early ketamine treatment – effects that depend
on not only the day of behavioral testing but also the day
in embryonic development when the NMDA receptor
antagonist was administered. During the initial stage of
the second water maze test (on P81), rats treated with ket-
amine on E18 found the hidden platform more quickly
than did animals receiving the same treatment on E19.
Moreover, they exhibited enhanced maze performance
compared to both groups of saline-treated rats. It is
important to note that ketamine treatment on E18 did not
induce faster swim speeds. Rather, the animals swam
more direct routes to the hidden platform.
Effects of ketamine on spontaneous open-field locomo-
tion were also age-dependent. In neonatal animals (P11),
ketamine administration in utero reduced subsequent
spontaneous movement. This effect was subtle (i.e., only
in evidence within the first 3-minutes of testing) and did
not depend on the subject's age at the time of the drug's
administration. However, when these animals were re-
tested on P60, the rats that received ketamine on E18 both
moved more than the rats that received ketamine on E19
and also moved more than saline-injected controls.
First, these data reveal long-term behavioral effects of a
single dose of ketamine administered in utero. Drug-
induced effects on water maze learning were observed
over 11 weeks after birth and locomotor effects were doc-
umented 9 weeks post partum. These findings are consist-
ent with others indicating that early NMDA receptor
blockade may produce behavioral alterations that are
detectable in adulthood [23,25,26]. Second, these data are
consistent with the hypothesis that the behavioral effects
of NMDA receptor blockade depend on the day in embry-
onic development when the antagonist is administered.
In particular, some of the findings reported here extend
our previous work indicating that ketamine treatment on
E18 may have different effects than administration of the
drug on E19 [21]. The same dose of ketamine adminis-
tered in the current study potentiated conditioned motor
responses of neonates if the drug had been given (through
the maternal circulation) on E18. However, ketamine
impaired acquisition of this learned response if it was
administered one day later on E19 [21]. Similar age-
dependent effects have been reported using different
behavioral indicators of learning [22,27].
The effects of early ketamine treatment on locomotion are
apparently not consistent throughout postnatal develop-
ment. Ketamine reduced locomotor movements in P11
rats but later (P60) selectively enhanced locomotion of
animals that received the drug on E18. The reasons for this
change in responding are unclear. In order to
accommodate the different size of the animals at P11 and
P60, there were differences in the dimensions of the open
field chambers used at each test. Also, the chamber walls
were clear during the P11 test and opaque at P60. But
beyond these differences in apparatus, maturation clearly
brings with it a variety of capabilities and propensities
many of which can modulate motor responding. For
example, at the end of 5 minutes, P11 rats reduce their
spontaneous locomotion to approximately 20% of its
original level. However, P60 rats are 80% as active during
this same time period. These data indicate a general ten-
dency for young rats to habituate (or fatigue) more rapidly
than older rats. Other behavioral studies have revealed
toxin-induced performance impairments that reveal
themselves only at certain stages of early postnatal
development but not at older ages [28]. More recently,
Beninger et al. [29] reported that rats administered MK-
801 on P3 and tested pre- (P35) and post-pubertally
(P56) exhibited different locomotor responses to amphet-
amine depending on the time of the behavioral test.
Our measures of swim speed may offer some insights
regarding the relative motor capacities and motivation of
our animals. Swim speeds did not significantly differ
between animals previously treated with ketamine or
saline. Likewise, fetal age at the time of the drug treatment
did not influence speed of swimming. Instead, rats
reduced their latencies to mount the platform by swim-
ming more-direct routes. Thus, the water maze data
reported here are less likely a reflection of the animal's
capacity or motivation to get to the platform and more
likely a reflection of learning ability.
It should be noted that water maze performance may be
influenced by a number of factors beyond cognitive abil-
ity. For example, drug-induced alteration of visual acuity,
motivation or motor capacities can alter performance of
this task [30]. The literature suggests that early NMDA
receptor blockade may alter development of the visual
system [31,32]. But measures of actual visual acuity fol-
lowing a single occurrence of NMDA receptor blockade in
the developing brain are lacking. The available data sug-
gest that visual plasticity is more significantly altered by
NMDA receptor antagonism than are visual maps [33] or
neural activity per se [34]. Our water maze procedures did
not necessarily place demands on the rat's visual system.
The location of the hidden platform was not changed
from trial to trial or between the P18 and P81 tests. There-
fore, once the platform was located, our subjects couldBMC Pharmacology 2004, 4:28 http://www.biomedcentral.com/1471-2210/4/28
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have adopted motor strategies to reach the goal on subse-
quent trials. Although water maze performance is typi-
cally cited as an indicator of spatial learning, our
paradigm does not eliminate the possibility that other
types of learning may also be involved.
We used accepted statistical methods to avoid spurious
inflation of sample size and to control for litter effects
[35,36] (see Methods section below). However, due to
constraints of resources, the small number of litters
employed may have reduced our power to detect subtle
differences in performance. Thus, this report should be
viewed as a conservative account of drug- and age-influ-
enced changes in behavior.
It is worth noting that it was initial responding on the
water maze and in the locomotor test chamber that was
most sensitive to our fetal ketamine treatment. ketamine-
treated rats exhibited significantly faster times to reach the
hidden platform (at age P81) – but only on the first trial.
Likewise, P11 rats treated with ketamine as fetuses,
exhibited fewer locomotor movements than did saline
controls – but only during the first 5 minutes of our test.
Our laboratory [37], as well as other investigators [38]
have reported a role for NMDA receptors in the determi-
nation of novelty. The current data seem to suggest that
these effects may extend to various behavioral testing par-
adigms. Moreover, since our tests were conducted weeks
after fetal ketamine treatment, our data indicate the per-
sistence of ketamine's effects on initial responding.
What neural, or other, mechanisms might subserve the
behavioral phenomenon outlined here? NMDA receptor
populations and physiology are neither static nor mature
during the perinatal period and blockade of these recep-
tors during particular days of development may produce
quite different effects [39,40]. For example, Sircar [41] has
shown that the binding of [3H] MK-801 (a potent/selec-
tive NMDA receptor antagonist) in synaptosomal mem-
branes is differentially altered by glutamate (and other)
agonists during various periods of development. These
data build on previous findings [42] indicating a dramatic
change in the number of PCP-binding sites in fetal rat
brain between the ages of E18 and E19. This is the same
time frame in which ketamine's effects on memory change
so significantly. Could these developmentally linked
changes in NMDA receptor populations and functional
roles mediate the ketamine paradox as well as the behav-
ioral phenomena presented here?
The identification of several NMDA receptor subtypes
with different functional roles and different patterns of
expression during the perinatal period may also eventu-
ally reveal aspects of the ketamine paradox's physiological
substrate [43-54]. Could a drug-induced change in the
population and/or distribution of NMDA receptor sub-
types mediate the ketamine paradox as well as long-term
behavioral effects? The current data do not address this
point directly. However, NR2B NMDA receptors (which
are known to be involved in learning, in general, and taste
memory formation, in particular) [55-57] have been iden-
tified as being especially sensitive to upregulation follow-
ing pharmacological antagonism [58,59]. Further, other
laboratories have reported that NMDA exposure can pro-
duce a reduction in NMDA receptors within 4 hours of
exposure [60]. Our data suggest the potential usefulness
of studies aimed at correlating ketamine-induced changes
in NMDA receptor subtype populations with behavioral
outcomes recorded at several times in development. Such
experiments are currently underway in our laboratory.
It should also be noted that ketamine can influence mater-
nal and fetal physiology in ways that go beyond the drug's
well-known effects on NMDA glutamate receptors [1].
Pulmonary vasodilator responses have been recorded fol-
lowing ketamine administration [61]. The drug can also
alter uterine tone in pregnant ewes by increasing cardiac
output and mean arterial pressure [62]. Although these
cardiovascular effects were slight and transient, they may
have contributed in yet-unknown ways to some of the
long-term behavioral changes we report here. Likewise,
ketamine not only affects NMDA receptors but may also
inhibit non-NMDA glutamate receptors [63], the high-
affinity states of the dopamine D2 receptor, and other G-
protein-linked receptors [64]. While ketamine's actions
on NMDA receptors are certainly prominent, acute
changes in vascular tone and the drug's actions on other
brain receptors are capable of influencing fetal develop-
ment in ways not addressed by the current experiments.
If early ketamine exposure influences NMDA receptor
populations or functioning, post-synaptic second messen-
ger pathways would also be engaged as mediators of
behavioral change [65]. Downstream calcium and cal-
modulin signaling, calcium-dependent kinases, and ulti-
mately changes in gene expression are known to produce
synaptic restructuring [66]. This cascade of NMDA-recep-
tor-initiated biochemical events provides a likely avenue
for further investigation as we examine the physiological
substrate of the behavioral phenomena described here.
The variables of subject age and ketamine dose interact in
complex ways to produce predictions of neurotoxicity. If
NMDA antagonists are used to suppress neuronal activity
during a critical developmental period of synaptogenesis,
the timing and sequence of synaptic connection is dis-
rupted [67]. This causes neurons to receive an internal sig-
nal to commit suicide – a form of programmed cell death
called apoptosis [68]. Ketamine, and other NMDA recep-
tor blocking drugs, are reported to produce these neuro-BMC Pharmacology 2004, 4:28 http://www.biomedcentral.com/1471-2210/4/28
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toxic effects [69] under certain circumstances. In the rat,
the period of brain sensitivity is largely confined to the
postnatal period (i.e., from P1 to P14) [70]. Our single
dose of ketamine was administered on either E18 or E19,
i.e., subject ages that, to the best of our knowledge, have
not been systematically manipulated in studies aimed at
investigating ketamine's ability to produce apoptosis.
These studies should be done to confirm the role that
apoptosis may/may not play in producing the long-term
behavioral changes we report here.
In addition to subject age, the dose of ketamine is another
important factor in determining the likelihood of apopto-
sis induction as well as the generalizability of our data to
clinical settings. In order to produce an increase in apop-
totic neurons in neonatal rats, ketamine must be adminis-
tered in multiple injections over a period of 9 hours [13].
Our study used a single dose of ketamine (delivered to a
pregnant rat) that was significantly higher (100 mg/kg)
that those used previously in neonates [69]. However,
from previous biochemical studies we know that our
dosing regimen in pregnant rats [27] produced a concen-
tration of fetal brain ketamine roughly comparable to that
seen in blood following repeated doses of 20 mg/kg
administered to neonatal rats (14 µg/g) [69]. These blood
levels were approximately seven-fold greater than anes-
thetic blood levels in humans [71,72]. Therefore, by
extrapolation, we may predict that our dose of ketamine
produced tissue levels of the drug that significantly
exceeded those typically produced in human patients who
encounter the drug in a clinical setting. Of course, this
does not eliminate the possibility that the human recrea-
tional use of ketamine (street name: "Special K") [68] may
produce blood and brain levels that are significantly
higher than those encountered in the clinic. Nor does it
exclude the possibility of differing drug sensitivities of rats
and humans. Both these factors will influence the clinical
relevance of the studies reported here.
Conclusions
These studies were aimed at determining the long-term
behavioral effects of ketamine administration on E18 and
E19 as a means of assessing the durability, intensity and
generalizability of the ketamine paradox [21]. Our previ-
ous work indicated that ketamine administration
enhanced the formation of a conditioned taste aversion in
E18 fetuses but not those treated on E19 or later [20-
22,29]. The current data reveal several subtle, but consist-
ent, residual behavioral changes produced by of a single
large dose of ketamine administered during the rat's late
pre-natal period. In terms of ketamine effects on sponta-
neous locomotion, we found that, irrespective of the day
of fetal dosing employed, ketamine reduced horizontal
movements when animals were tested on P11. However,
when the animals were tested later, on P60, rats that had
received ketamine on E18 differentiated themselves from
the E19 ketamine-treated animals (and saline-treated con-
trols) by exhibiting an increase in locomotion – especially
in the early minutes of behavioral testing in the open
field. Ketamine's long-term influence on water maze
learning/retention was limited in scope, but palpable, on
the first trial of the P81 test.
Despite the reliable enhancement of CTA learning that
has been reported in fetuses and neonates treated with
ketamine on E18 [29], this same dosing regimen pro-
duced limited improvements in learning/retention of a
water maze when the animals were tested as young adults.
The usefulness of ketamine as a cognitive enhancer,
administered in the perinatal period, appears to be lim-
ited not only by its known toxic effects at critical stages of
development [68] but also by its influence on spontane-
ous movement and the drug's weak memory-enhancing
properties over the long term.
Methods
Subjects
The subjects were Sprague-Dawley rats (male and female)
obtained from timed pregnant female rats supplied by
Zivic Laboratories (Zelienople, PA). Litters (N = 2/treat-
ment group) were not culled and ranged in size from 9 to
13 pups. [See behavioral testing sections below for details
about the number of animals in each treatment group.]
The variable number of subjects/group was due to differ-
ent litter sizes and several logistical constraints that did
not always allow the testing of all rats in each litter. Statis-
tical adjustments were made in order to compensate for
the unequal Ns in the treatment groups (see below). The
date of conception (i.e., the date a vaginal plug was first
detected) was designated as "embryonic day 0" (E0). Post-
natal day 0 (P0) was the day of birth (typically E21.5). The
pregnant animals from which our subjects were derived
were individually housed in plastic 'shoe-box' cages
(44.45 cm long × 21.59 cm wide × 20.32 cm high). After
birth, perinatal rats were housed with the dam until they
were sexed and weaned between P21-25 (this is within
recommended weaning dates, see [73], at which point the
pups were group-housed (separated by sex) in the stand-
ard-sized cages described above. Throughout the experi-
ment home cage temperature was maintained at 23–26°C
under a 12:12-h light:dark cycle (lights on at 0600 h).
The Baldwin-Wallace College Institutional Animal Care
and Use Committee approved these experiments. The ani-
mals involved in this study were procured, maintained
and used in accordance with the Animal Welfare Act and
the Guide for the Care and Use of Laboratory Animals, pre-
pared by the Institute of Laboratory Animal Resources –
National Research Council.BMC Pharmacology 2004, 4:28 http://www.biomedcentral.com/1471-2210/4/28
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Drug treatments
Pregnant dams received ketamine HCl (100 mg/kg, i.p.;
Sigma Chemical Company), or an equal volume of phys-
iological saline, (0.9% NaCl, i.p.) on either E18 or E19.
Saline injections controlled for the stress of pre-natal
manipulation. Thus, there were 4 treatment groups desig-
nated hereafter as follows: E18/ketamine, E18/saline,
E19/ketamine, or E19/saline. Rats from two litters were
used in each of the treatment groups. In order to separate
out treatment effects from litter effects special statistical
measures were employed (see Statistical Analyses, below)
[35,36]. The dose of ketamine employed (100 mg/kg, i.p.)
was selected based on previous experiments [21] in which
the drug produced very different behavioral effects when
administered to E18 or E19 fetuses through the maternal
circulation. Using high-pressure liquid chromatography
(HPLC) measures we have previously determined the
level of ketamine (approximately 14 µg/g tissue) found in
the brains of fetuses following a maternal injection of 100
mg/kg ketamine during the late pre-natal period [27].
Behavioral testing
We recorded performance in a water maze and also spon-
taneous locomotor movements in an open field. Each of
these behavioral tests was conducted twice, i.e., once in
each of two different time periods: Juvenile Period (pre-
pubertal), within the first three weeks after birth and
Young-adult Period (post-pubertal), between 2–3 months
of age. We selected these two behavioral test periods based
on knowledge of the patterns of development of NMDA
receptor subtypes. The NR2B receptor subtype has been
implicated in learning and memory [55]. These receptors
are present during the late pre-natal period and they rise
steadily up to P20 when they achieve adult levels [43,74].
Therefore, our behavioral measures sampled times both
before and after maturation of this receptor system. The
behavioral tests conducted within the juvenile or post-
pubertal periods were separated in time (by a minimum
of 1 week) to reduce the influence of one on the other.
Most, but not all, animals were tested and then retested.
However, statistical analyses indicated that there were no
differences between the animals that were tested once or
twice. Therefore, these groups were combined for subse-
quent statistical analyses. Additional behavioral testing
(i.e., conditioned taste aversion) was performed on some
of these animals but there were some logistical problems
with the experiment. These data did not reveal reliable
group differences and are not reported here.
Water maze
At age P18, and then again at P81, we evaluated water
maze performance by testing the following number of rats
per group: P18: E18/ketamine: (N = 12); E18/saline: (N =
16); E19/ketamine: (N = 14); E19/saline: (N = 15); P81:
E18/ketamine: (N = 12); E18/saline: (N = 22); E19/keta-
mine: (N = 17); E19/saline: (N = 20). Our data
corroborate other studies indicating that rats younger
than P20 are capable of learning a water maze [75,76].
The water maze was an oval stock-watering tank (manu-
factured by Rubbermaid, Inc.) measuring 94 cm × 74 cm
× 60 cm deep. It was sized to shorten swim distances to
the hidden platform and reduce the likelihood of fatigue
in our young animals. The tank was filled to 39.5 cm (1
cm above a hidden platform) with water that was made
opaque and white by adding 710 ml of evaporated milk
(Nestle's Carnation® brand). The water temperature was
maintained at 26 ± 1°C. The escape platform was a clear
plastic disc (12.5 cm diameter × 1.2 cm) mounted on a
stand. The platform remained in the same location
(approximately 10 cm from the side of the tank) through-
out the test session. The edges of the platform had white
rubberized tape attached in order to aid the rats as they
mounted it. The tank was in a room lighted with
fluorescent lights and surrounded by a rich array of labo-
ratory furnishings.
All test sessions were video recorded and the tapes were
later used for analysis of latency to escape, stop time, time
on platform, path length and swim speed (see Statistical
Analyses below). "Escape latency" was defined as the time
(in seconds) it took the rat, once in the water, to mount
and gain balance on the platform. "Stop time" was the
total time/trial that subjects spent treading water (i.e., not
making forward progress). "Time on the platform" was
defined as the time (up to 30 sec) the animal remained on
the platform after initial mounting. "Path length" was the
total distance (cm) swum before the subject mounted the
platform. "Swim speed" was expressed in cm/sec and
reflected the rate of forward progress towards the
platform.
At the beginning of each water maze test session, a rat was
placed in the water facing the wall of the tank opposite the
one near the hidden platform. A swim trial lasted until the
rat reached the hidden platform or until 90 seconds had
passed. If the animal reached the platform in the allotted
90 seconds, it was allowed to remain on the platform for
up to 30 seconds and was then returned to a holding cage
(a dry, plastic "shoe-box" cage). The holding cage sat
upon a heating pad set at 33.5°C., producing a floor tem-
perature of approximately 28.5 ± 1°C. If the animal did
not reach the platform in 90 seconds it was removed from
the water and returned to the cage. If the animal jumped
off the platform before 30 seconds, it was removed from
the water and returned to its holding cage. All rats were
given a 60-second rest period before the next trial was ini-
tiated. Each rat experienced ten swim trials during each of
the two test sessions. At the end of the 10 trials, each ratBMC Pharmacology 2004, 4:28 http://www.biomedcentral.com/1471-2210/4/28
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was thoroughly dried with a towel and a blow dryer and
then returned to its home cage. Escape latencies and time
on the hidden platform were recorded for each trial.
Spontaneous locomotion
At age P11, we measured the spontaneous locomotor
activity of the following number of rat pups in each group:
E18/ketamine: (N = 18); E18/saline: (N = 25); E19/keta-
mine: (N = 21); E19/saline: (N = 24). The test chamber
consisted of a plastic 'shoe-box' cage (44.45 cm long ×
21.59 cm wide × 20.32 cm high) with transparent walls
and open top. This chamber had a grid on its floor com-
posed of 3 × 6 squares (each measuring 7.1 cm × 7.1 cm).
Young rats have limited abilities to thermoregulate [77].
Therefore, the activity chamber was placed on a heating
pad set at 33.5°C., producing a floor temperature of
approximately 28.5 ± 1°C. An individual pup was initially
positioned in the center square of the chamber. Locomo-
tor activity was recorded for 30 minutes. Test sessions
were video recorded and tapes were later scored (see
below). After each session, the animal was weighed and
then returned to its home cage. In preparation for the next
animal, the activity chamber was cleaned by spraying the
cage with 50% ETOH, wiping it clean with paper towels,
and allowing it to air-dry for approximately 10 minutes.
At age P60, we again measured the spontaneous locomo-
tor activity of the following number of rats in each group:
E18/ketamine: (N = 12); E18/saline: (N = 21); E19/keta-
mine: (N = 17); E19/saline: (N = 22). For this second test,
a larger test chamber (64 cm long × 46 cm wide × 42 cm
high) was used. The walls were opaque plastic and the top
open. This chamber had a grid on its floor that consisted
of 3 × 3 rectangles (each measuring 21 cm × 15 cm). As
before, rats were individually placed in the center square
of the chamber at the beginning of the 30-minute test ses-
sion. After each session, the animal was weighed and then
returned to its home cage. In preparation for the next ani-
mal, the activity chamber was cleaned as described above.
Videotapes of locomotor movements were later viewed
and independently scored by observers blind to the exper-
imental condition of the animal. We counted line cross-
ings to assess the amount of horizontal locomotion
exhibited by each animal. A "line-cross" was counted
when any part of the rat, except the tail, crossed a line.
Rearing was operationally defined as any time the rat
raised both front paws from the chamber floor. In P11
rats, rearing was very rare and therefore not scored. How-
ever, this behavior was recorded during the P60 test.
Statistical analyses
Escape latencies and time on the hidden platform were
recorded for each trial in the water maze. Group differ-
ences in water maze performance were most evident early
in training. After the first few trials, rats in all treatment
groups moved promptly to the hidden platform with a
latency of less than 20 seconds. For this reason, our statis-
tical analyses focused on the initial trials of each session.
Animals removed from the maze after not finding the hid-
den platform in 90 seconds were, nevertheless, assigned a
time of 90 seconds for purposes of data analysis.
Swim distances, swim speeds, and time spent treading
water (stop times) were also calculated for the first 3 swim
trials. Towards this end, videotapes were viewed and inde-
pendently evaluated by raters blind to the experimental
condition of the animal. Swim paths were hand-drawn on
acetate placed on a video screen during playback of the
videotape. The paths were digitized using a light pen pro-
viding input to NIH Image software (Bethesda, MD). The
lengths of the paths were compared with a calibrated
length on the video record in order to calculate the swim
distance. An evaluation of the inter-rater reliability of our
video scoring methods indicated a high correlation [r(10)
= 0.924, p < 0.001]. These methods produced swim dis-
tances that were not significantly different [t(9) = 1.02, p
> 0.05] between observers. For some of our swim speed
analyses, we subtracted out any time that the animal
stopped swimming mid-trial, and treaded water at the
side of the tank. Dividing the swim distance by the
adjusted time to mount the hidden platform produced
swim speed.
Two observers, blind to the experimental condition of the
animals, evaluated each of the tapes of animals locomot-
ing in the open field by counting line crossings and rears.
The counts of these 2 observers were then averaged and
this data point was used in our statistical analysis. There
was high degree of correlation between the ratings of our
2 observers. P11 locomotor test: r(85) = 0.91, p < 0.01;
P60 locomotor test: r(72) = 0.90, p < 0.01.
Unless otherwise stated, locomotor data for the two differ-
ent test periods (P11 and P60) and water maze data for
the 2 different test periods (P18 and P81) were analyzed
via separate repeated-measures, three-way ANOVAs [Drug
(100 mg/kg ketamine HCl, saline control) X Treatment
age (E18, E19) X Time] with time blocks as the repeated
factor and compensation for unequal Ns.
We used several rats from each litter and employed statis-
tical corrections in order to avoid spurious inflation of
sample size [35]. Since all the rats in a particular litter
received the same drug treatment, we included litter as an
independent and nested factor in the analysis. This
approach controls for litter effects and offers a direct sta-
tistical test of the significance of such effects [35]. Denen-
berg [36] has recommended this procedure to allow the
partitioning of litter and treatment effects and therebyBMC Pharmacology 2004, 4:28 http://www.biomedcentral.com/1471-2210/4/28
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allowing investigators to make use of the data from mul-
tiple animals in a litter. When significant litter effects were
detected, we used the Mean Square (MS) associated with
the litters as the error term rather than the MS of the
subjects. However, if there was not a statistically signifi-
cant litter effect, the data were subsequently reanalyzed
without this component as part of the general linear
model (GLM; software provided by SAS™, SAS Institute,
Carey, NC; and, SPSS™ Inc., Chicago, IL).
An initial inclusion of subject sex as a factor in our statis-
tical analyses indicated no significant differences between
male and female subjects. Therefore, the subsequent anal-
yses reported here were run without this factor.
Platform navigation for juvenile rats might be more chal-
lenging than the task presented to older rats. A small water
maze was used in these studies and the same start-to-plat-
form distance was used for all tests. Still, the P18 rat may
have found it significantly more challenging than the P81
rat to traverse this distance. For this reason, we intention-
ally avoided comparing the water maze data of our juve-
nile and young-adult rats. Likewise, we did not make
statistical comparisons between the locomotor responses
of animals run at the 2 different ages since the use of dif-
ferent-sized apparatuses would presumably influence
these data.
If a repeated-measure ANOVA revealed a significant trial
effect (indicating a change over time) a two-way ANOVA
[Drug (100 mg/kg ketamine HCl, saline control) X Treat-
ment age (E18, E19)] was run to analyze the group differ-
ences during a particular trial. Individual group
comparisons were accomplished by using either the
Tukey-Kramer Multiple Comparisons Test or t-tests [78]
using the Bonferroni compensation for multiple compar-
isons. Our previous studies with ketamine-treated fetuses
lead us to a priori hypotheses regarding possible behavio-
ral differences between rats treated with ketamine on E18
versus E19 [21]. When a priori planned comparisons were
made, one-tail probabilities were computed. An α = 0.05
was used throughout these analyses presented here.
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